Iclaprim is a targeted Gram-positive antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA). Iclaprim works in a different way than most other antibiotics and rapidly kills bacteria in vitro.

Motif BioSciences Inc., Motif Bio plc’s wholly owned subsidiary, has ceased all operations and has engaged Tamarack Associates to facilitate the sale of iclaprim and its other assets.

Legacy Program Inquiries

For inquiries related to Motif BioSciences Inc. and iclaprim, contact John Palmer of Tamarack Associates at [email protected].